

Bölüm 7

BİFOSFONAT İLAÇLAR VE BİFOSFONAT İNDÜKLÜ ÇENE OSTEONEKROZLARI

Hamdi SARI¹

Bifosfonatlar günümüzde çoğu hastalığın tedavisinde sıklıkla kullanılmaktadırlar. Oral bifosfonatlardan etidronat ve tiludronat, paget hastalığının aktif döneminde (Chapurlat & Meunier, 1998) alendronat ve ibandronat FDA onaylı olarak osteoporoz tedavisinde ve off label olarak osteopeni tedavisinde kullanılmaktadırlar. (Lieberman et al., 1995) Ayrıca kemik kaynaklı çeşitli malignansilere bağlı hiperkalseminin tedavisinde intravenöz verilen pamidronat ve zoledronat uygulamasının FDA' den onayı vardır.(Major, 2002) Bu ilaçların temel biyolojik etki mekanizması kemik rezorpsiyonunu ve kemik turnover'ını inhibe etmektir. Osteoklastik aktiviteyi inhibe edici etkileri vardır.(Woo, Hellstein, & Kalmar, 2006)

Tarihçe

Bifosfonatlara bağlı çenelerdeki ilk nekroz Marx ve Stern tarafından tanımlanmıştır.(R E Marx & Stern, 2002) Marx ve Stern tarafından yazılan kitabın bu hastalığın ilk tanımlanmış olduğu kitap olduğu düşünülse de “phossy jaw” olarak bilinen aynı bu hastalık gibi belirtiler veren bir sanayi hastalığı daha önceden tanımlanmıştı.(Dearden, 1899; Hellstein & Marek, 2005; Robert E. Marx & Stern, 2012) İngiltere ve A.B.D'nde kibrit fabrikalarında ve fosfat madencilerinde işçilerde maruz kaldıkları süre ile doğru orantılı olarak ağızlarında iyileşmeyen yaralar ve ekspo kemik varlığı olduğu rapor edilmiştir. (Dearden, 1899, 1901) Fosfat madenlerinde ve kibrit fabrikalarında havada uçuşan fosfonatlara her gün kronik olarak maruziyet, kemikte bifosfonat bileşiklerinin birikimine neden olarak hastalara bifosfonat tedavisinde olduğu gibi bir tablo ortaya çıkarmıştır.(Hamilton & Hardy, 1949; Robert E. Marx, 2008; Miles, 1972)

¹ Dr. Öğr. Üyesi, Uşak Üniversitesi Diş Hekimliği Fakültesi Ağız, Diş ve Çene Cerrahisi Ab., hmdsrkn@gmail.com

KAYNAKLAR

1. A., F., P., K., & E., T. (1998). The use of cyclical etidronate in osteoporosis: Changes after completion of 3 years treatment. *British Journal of Rheumatology*.
2. Abrahamsen, B. (2010). Adverse effects of bisphosphonates. *Calcified Tissue International*. <https://doi.org/10.1007/s00223-010-9364-1>
3. Adler, R. A. (2016). Bisphosphonates and atypical femoral fractures. *Current Opinion in Endocrinology, Diabetes and Obesity*. <https://doi.org/10.1097/MED.0000000000000287>
4. Aoyagi, T., Morii, T., Ohtsuka, K., Ohnishi, H., Tajima, T., Yoshiyama, A., ... Ichimura, S. (2013). Lung cancer cell line sensitivity to zoledronic acid is BAX-dependent. *Anticancer Research*.
5. Bobba, R. S., Beattie, K., Parkinson, B., Kumbhare, D., & Adachi, J. D. (2006). Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. *Drug Safety*. <https://doi.org/10.2165/00002018-200629120-00005>
6. Body, J.-J., Bartl, R., Burckhardt, P., Delmas, P. D., Diel, I. J., Fleisch, H., ... Pateron, A. H. (1998). Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. *Journal of Clinical Oncology*, 17(4), 1328–1329.
7. Bollerslev, J., & Andersen, P. E. (1988). Radiological, biochemical and hereditary evidence of two types of autosomal dominant osteopetrosis. *Bone*. [https://doi.org/10.1016/8756-3282\(88\)90021-X](https://doi.org/10.1016/8756-3282(88)90021-X)
8. Carlson, E. R., Fleisher, K. E., & Ruggiero, S. L. (2013). Metastatic cancer identified in osteonecrosis specimens of the jaws in patients receiving intravenous bisphosphonate medications. *Journal of Oral and Maxillofacial Surgery*. <https://doi.org/10.1016/j.joms.2013.05.014>
9. Chapurlat, R., & Meunier, P. J. (1998). [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis]. *Rev Chir Orthop Reparatrice Appar Mot*.
10. Cleiren, E., Bénichou, O., Hul, E. Van, Gram, J., Bollerslev, J., Singer, F. R., ... Hul, W. Van. (2001). Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the CICN7 chloride channel gene. *Human Molecular Genetics*. <https://doi.org/10.1093/hmg/10.25.2861>
11. Crépin, S., Laroche, M. L., Sarry, B., & Merle, L. (2010). Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: Case report and literature review. *European Journal of Clinical Pharmacology*. <https://doi.org/10.1007/s00228-010-0822-5>
12. Cryer, B., & Bauer, D. C. (2002). Oral bisphosphonates and upper gastrointestinal tract problems: What is the evidence? *Mayo Clinic Proceedings*. <https://doi.org/10.4065/77.10.1031>
13. De Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., ... Wang, K. K. (1996). Esophagitis associated with the use of alendronate. *New England Journal of Medicine*, 335(14), 1016–1021.
14. Dearden, W. F. (1899). Fragilitas Ossium amongst Workers in Lucifer Match Factories. *British Medical Journal*, 2(2013), 270–271. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/20758614>
15. Dearden, W. F. (1901). The causation of phosphorus necrosis. *BMJ*, 2, 408.
16. Dixon, R. B. (1997). Bone turnover in elderly canine mandible and tibia. *J Dent Res*, 76, 336.

17. Drake, M. T., Clarke, B. L., & Khosla, S. (2008). Bisphosphonates: Mechanism of action and role in clinical practice. *Mayo Clinic Proceedings*. <https://doi.org/10.4065/83.9.1032>
18. Ebetino, F. H., Hogan, A. M. L., Sun, S., Tsoumpra, M. K., Duan, X., Triffitt, J. T., ... Russell, R. G. G. (2011). The relationship between the chemistry and biological activity of the bisphosphonates. *Bone*. <https://doi.org/10.1016/j.bone.2011.03.774>
19. Edwards, B. J., Hellstein, J. W., Jacobsen, P. L., Kaltman, S., Mariotti, A., Migliorati, C. A., & Jaw, A. D. A. C. on S. A. E. P. on B.-A. O. of the. (2008). Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. *The Journal of the American Dental Association*, 139(12), 1674–1677.
20. Engroff, S. L., & Kim, D. D. (2007). Treating Bisphosphonate Osteonecrosis of the Jaws: Is There a Role for Resection and Vascularized Reconstruction? *Journal of Oral and Maxillofacial Surgery*. <https://doi.org/10.1016/j.joms.2006.07.012>
21. F., C., R., L., S.J., de B., M.S., L., E.M., L., B., T., & S., R. (2014). Clinician's Guide to Prevention and Treatment of Osteoporosis. *Osteoporosis International*. <https://doi.org/10.1007/s00198-014-2794-2>
22. Fedele, S., Kumar, N., Davies, R., Fiske, J., Greening, S., & Porter, S. (2009). Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review. *Oral Diseases*, 15(8), 527–537.
23. Ferrari, S., Bianchi, B., Savi, A., Poli, T., Multinu, A., Balestreri, A., & Ferri, A. (2008). Fibula Free Flap With Endosseous Implants for Reconstructing a Resected Mandible in Bisphosphonate Osteonecrosis. *Journal of Oral and Maxillofacial Surgery*. <https://doi.org/10.1016/j.joms.2007.06.631>
24. Force, A. T. (2007). Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. *J Oral Maxillofac Surg*, 65, 369–376.
25. Glorieux, F. H., Bishop, N. J., Plotkin, H., Chabot, G., Lanoue, G., & Travers, R. (1998). Cyclic Administration of Pamidronate in Children with Severe Osteogenesis Imperfecta. *New England Journal of Medicine*. <https://doi.org/10.1056/NEJM199810013391402>
26. Glowacki, J. (2005). Bisphosphonates and bone. *Ortho J Harvard Med School*, 25, 64–67.
27. Hamilton, A., & Hardy, H. L. (1949). *Industrial Toxicology*, Paul B. Hoeber. Inc., New York Ed. 2, 138–149.
28. Hellstein, J. W., & Marek, C. L. (2005). Bisphosphonate Osteochemonecrosis (Bisphossy Jaw): Is This Phossy Jaw of the 21st Century? *Journal of Oral and Maxillofacial Surgery*, 63(5), 682–689. <https://doi.org/10.1016/j.joms.2005.01.010>
29. Khosla, S., Bilezikian, J. P., Dempster, D. W., Lewiecki, E. M., Miller, P. D., Neer, R. M., ... Potts, J. T. (2012). Benefits and risks of bisphosphonate therapy for osteoporosis. *The Journal of Clinical Endocrinology and Metabolism*, 97(7), 2272–2282. <https://doi.org/10.1210/jc.2012-1027>
30. Kumar, S. K. S., Gorur, A., Schaudinn, C., Shuler, C. F., Costerton, J. W., & Sedghizadeh, P. P. (2010). The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. *Current Osteoporosis Reports*. <https://doi.org/10.1007/s11914-010-0008-1>

31. Landesberg, R., Eisig, S., Fennoy, I., & Siris, E. (2009). Alternative Indications for Bisphosphonate Therapy. *Journal of Oral and Maxillofacial Surgery*. <https://doi.org/10.1016/j.joms.2008.12.006>
32. Lasseter, K. C., Portas, A. G., Denker, A., Santhanagopal, A., & Daifotis, A. (2005). Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates. *Clinical Drug Investigation*, 25(2), 107–114.
33. Lewiecki, E. M. (2010). Bisphosphonates for the treatment of osteoporosis: Insights for clinicians. *Therapeutic Advances in Chronic Disease*. <https://doi.org/10.1177/2040622310374783>
34. Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., ... Karpf, D. B. (1995). Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis. *New England Journal of Medicine*. <https://doi.org/10.1056/NEJM199511303332201>
35. Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Rogers, M. J. (1998). Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. *Journal of Bone and Mineral Research*, 13(4), 581–589.
36. Major, P. (2002). The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. *Oncologist*. <https://doi.org/10.1634/theoncologist.7-6-481>
37. Makigusa, K. (2009). Histologic comparison of biologic width around teeth versus implant: The effect on bone preservation. *J Implant Reconstr Dent*. <https://doi.org/10.1139/P11-077>
38. Marini, J. C. (2003). Do bisphosphonates make children's bones better or brittle? *The New England Journal of Medicine*. <https://doi.org/10.1056/NEJMp038103>
39. Marx, R. E. (2008). Uncovering the Cause of “Phossy Jaw” Circa 1858 to 1906: Oral and Maxillofacial Surgery Closed Case Files—Case Closed. *Journal of Oral and Maxillofacial Surgery*, 66(11), 2356–2363. <https://doi.org/10.1016/j.joms.2007.11.006>
40. Marx, R. E., & Stern, D. (2012). *Oral and maxillofacial pathology : a rationale for diagnosis and treatment*. Quintessence Pub. Co. Retrieved from http://www.quintpub.com/display_detail.php3?psku=B5129#.XBUiMWgzZPY
41. Marx, R. E., & Stern, D. S. (2002). Biopsy principles and techniques. *Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment*. Chicago: Quintessence, 36–38.
42. Miles, A. E. (1972). Phosphorus necrosis of the jaw: “phossy jaw.” *British Dental Journal*. <https://doi.org/10.1038/sj.bdj.4802906>
43. Mkele, G. (2013). Bisphosphonates and their use. *SA Pharmaceutical Journal*, 80(8), 24–26.
44. Novartis, A. G. (2004). Aredia: pamidronate disodium for injection, For intravenous infusion. *Product Information Sheet, Novartis AG, 1*.
45. Oncology, N. (n.d.). About ZOMETA®(zoledronic acid) 4 mg/5mL Injection.
46. Rizzoli, R. (2011). Bisphosphonates for post-menopausal osteoporosis: Are they all the same? *QJM*. <https://doi.org/10.1093/qjmed/hcq259>
47. Rizzoli, R., Reginster, J. Y., Boonen, S., Bréart, G., Diez-Perez, A., Felsenberg, D., ... Cooper, C. (2011). Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. *Calcified Tissue International*. <https://doi.org/10.1007/s00223-011-9499-8>

48. Rocha, M. L., Malacara, J. M., Sánchez-Marin, F. J., de la Torre, C. J. V., & Fajardo, M. E. (2004). Effect of Alendronate on Periodontal Disease in Postmenopausal Women: A Randomized Placebo-Controlled Trial. *Journal of Periodontology*. <https://doi.org/10.1902/jop.2004.75.12.1579>
49. Rogers, M. J., Crockett, J. C., Coxon, F. P., & Mönkkönen, J. (2011). Biochemical and molecular mechanisms of action of bisphosphonates. *Bone*. <https://doi.org/10.1016/j.bone.2010.11.008>
50. Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O’Ryan, F. (2014). American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. *Journal of Oral and Maxillofacial Surgery*, 72(10), 1938–1956.
51. Russell, R. G. G., Croucher, P. I., & Rogers, M. J. (1999). Bisphosphonates: pharmacology, mechanisms of action and clinical uses. *Osteoporosis International*, 9(8), S66–S80.
52. Saridoğan, M., & Gün, K. (2010). Long-term Treatment with Bisphosphonates and Their Side Effects in Postmenopausal Osteoporosis-Review. *Türk Osteoporoz Dergisi*, 16(3), 66–71.
53. Sedghizadeh, P. P., Kumar, S. K. S., Gorur, A., Schaudinn, C., Shuler, C. F., & Costerton, J. W. (2008). Identification of Microbial Biofilms in Osteonecrosis of the Jaws Secondary to Bisphosphonate Therapy. *Journal of Oral and Maxillofacial Surgery*. <https://doi.org/10.1016/j.joms.2007.11.035>
54. Seth, R., Futran, N. D., Alam, D. S., & Knott, P. D. (2010). Outcomes of vascularized bone graft reconstruction of the mandible in bisphosphonate-related osteonecrosis of the jaws. *Laryngoscope*. <https://doi.org/10.1002/lary.21062>
55. Sözen, T. (2008). TEMD Osteoporoz ve Diğer Metabolik Kemik Hastalıkları Çalışma Grubu. *Osteoporoz. Sık Görülen Metabolik Kemik Hastalıkları Kullanım Klavuzu*, 97.
56. Vassiliou, V., Tselis, N., & Kardamakis, D. (2010). Osteonecrosis of the jaws: Clinicopathologic and radiologic characteristics, preventive and therapeutic strategies. *Strahlentherapie Und Onkologie*. <https://doi.org/10.1007/s00066-010-2066-9>
57. Villa, J. C., Gianakos, A., & Lane, J. M. (2016). Bisphosphonate treatment in osteoporosis: optimal duration of therapy and the incorporation of a drug holiday. *HSS Journal®*, 12(1), 66–73.
58. Vondracek, S. F., Minne, P., & McDermott, M. T. (2008). Clinical challenges in the management of osteoporosis. *Clinical Interventions in Aging*.
59. Walter, C., Al-Nawas, B., Bois, A. Du, Buch, L., Harter, P., & Grötz, K. A. (2009). Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. *Cancer*. <https://doi.org/10.1002/cncr.24119>
60. Walter, C., Al-Nawas, B., Grötz, K. A., Thomas, C., Thüroff, J. W., Zinser, V., ... Wagner, W. (2008). Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate. *European Urology*. <https://doi.org/10.1016/j.eururo.2008.06.070>
61. Wanger, G., Gorby, Y., El-Naggar, M. Y., Yuzvinsky, T. D., Schaudinn, C., Gorur, A., & Sedghizadeh, P. P. (2013). Electrically conductive bacterial nanowires in bisphosphonate-related osteonecrosis of the jaw biofilms. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*. <https://doi.org/10.1016/j.oooo.2012.08.446>
62. Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H., & Mumm, S. (2003). Bisphosphonate-induced osteopetrosis. *New England Journal of Medicine*, 349(5), 457–463.

63. Woo, S. Bin, Hellstein, J. W., & Kalmar, J. R. (2006). Systematic review: Bisphosphonates and osteonecrosis of the jaws. *Annals of Internal Medicine*. <https://doi.org/10.7326/0003-4819-144-10-200605160-00009>
64. Zacharin, M., & O'Sullivan, M. (2000). Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. *Journal of Pediatrics*. <https://doi.org/10.1067/mpd.2000.107836>